Burn Care Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

High Incidence of Burn Injuries Worldwide

Wildfires in Central Canada burned 2.7 million hectares in 2025 and forced 33,000 evacuations, pushing emergency departments to an eightfold surge in burn-related visits. The January 2025 Los Angeles fires destroyed 16,250 structures and exposed 41,000 residents, illustrating the escalating clinical burden.^{[1]United Nations University, “Wildfire Losses and Health Impacts 2025,” unu.edu} Chronic wound management, including burns, carries an annual economic load surpassing USD 20 billion in the United States. Pediatric trials with non-thermal plasma cut skin-graft needs from 40% to 10%.^{[2]Y. Chen et al., “Plasma Therapy in Pediatric Burns,” mdpi.com} These data point toward sustained allocation of resources across global health systems.

Increasing Adoption of Advanced Wound Dressings & Skin Grafts

Smith+Nephew posted 3.8% underlying growth in its Advanced Wound Management unit during Q1 2025, reflecting robust demand for foams and NPWT devices. The Red Dot-awarded RENASYS EDGE system addresses the needs of 8.2 million American chronic-wound patients at a USD 33 billion financial burden. Silver-nanoparticle and collagen matrices achieve 50-95% healing rates across diverse cohorts. Solventum’s V.A.C. Peel & Place cut application time by 61% and costs by 41% while supporting seven-day wear. Healthcare purchasers therefore continue to favour clinically proven dressings that also reduce total cost of care.

Rapid Technological Advances (NPWT, Antimicrobial Hydrogels, 3-D Bioprinting)

Caltech’s iCares smart bandage delivers real-time diagnostics and machine-learning-based healing predictions with expert accuracy.^{[3]Science Translational Medicine, “Smart Bandage for Burn Healing,” caltech.edu} Three-dimensional bioprinted nanofiber scaffolds show improved adhesion and controlled degradation for full-thickness wounds. Conductive hydrogels containing deep-eutectic solvents stimulate tissue repair through low-intensity electrical fields. MedStar Health paired dynamic thermography with laser Doppler imaging to anticipate wound conversion, enabling earlier intervention. Such tools shorten healing times and limit infection-related readmissions.

Favourable Reimbursement & Government Safety Initiatives

CMS reclassified skin substitutes as wound-care management products in April 2025, expanding application limits and introducing new documentation standards. The 2025 Physician Fee Schedule added caregiver training codes G0541-G0543, supporting telehealth engagement. The Military Burn Research Program committed USD 650 million to triage and treatment technologies designed for austere settings. Compliant suppliers gain advantage under the updated rules.

High Cost of Advanced Burn-Care Products & Biologics

Medicare investigations into inflated skin-substitute pricing spotlight financial barriers in the burn care market. Integra LifeSciences saw Tissue Technologies revenue fall 15.3% in Q1 2024 due to production outages, underscoring supply risk. DOJ action against Vohra Wound Physicians accentuates compliance pressure. Accountable Care Organizations advocate stricter controls to safeguard budgets. High sticker prices thus temper biologic uptake, especially outside high-income economies.

Limited Reimbursement & Skilled Staff in Emerging Economies

Asia-Pacific still shows the fastest trajectory yet faces gaps in certified wound nurses, hindering the burn care market. Home-health teams struggle with complex dressing protocols, and limited insurance hampers broad technology deployment. A regional consensus on standardized burn assessment called for investment in professional development and telehealth infrastructure. Solutions such as WoundConnect reduced in-person visits while keeping clinical outcomes stable. Nevertheless, progress remains uneven across developing regions.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Burn Care Market Segment Analysis

Advanced dressings held 52.21% market share, of the burn care market in 2025. Iterative upgrades in hydrofiber foams, antimicrobial silver layers, and moisture-handling backings maintain clinician confidence and secure reimbursement. Smith+Nephew expanded its foam line in 2024, reinforcing stickiness within hospital formularies. Traditional dressings persist in budget-sensitive outpatient settings, sustaining baseline demand. Therapy devices, notably portable NPWT units, speed patient discharge and bolster outpatient revenue models. Topical antimicrobial gels remain standard prophylaxis for minor wounds.

Biologics, while smaller in absolute value, recorded 9.41% CAGR from 2026 to 2031, the highest across product categories. FDA clearance of AVITA Medical’s Cohealyx dermal matrix in December 2024 widens indications and triples the firm’s total addressable population. Bioengineered skin delivers outcomes similar to autografting without donor-site morbidity. However, the burn care market size for biologics stays curtailed by high manufacturing cost and complex cold-chain logistics. As payers refine coverage criteria, vendors that generate robust comparative-effectiveness data will gain share.

Partial-thickness injuries comprised 43.61% of the burn care market in 2025, benefiting from established moist-healing protocols and outpatient care pathways. Patients typically receive hydrogel or silicone dressings that minimize trauma on changes, reducing infection risk and scarring. Minor wounds, often treated at home or in urgent-care settings, drive demand for accessible dressings and analgesic sprays. Clinician familiarity, predictable healing times, and lower material cost sustain steady revenue.

Full-thickness burns, although fewer in case volume, will rise at an 8.29% CAGR to 2031. The January 2025 Los Angeles fires exposed tens of thousands of residents, highlighting the need for highly specialized reconstruction. Advanced dermal matrices from Integra anchor staged reconstruction algorithms that now achieve higher survival rates. Growth accelerates as critical-care capabilities improve outside traditional burn centers, expanding geographical availability of complex surgeries. The burn care market size for these severe presentations therefore shows disproportionate revenue contribution compared with case count.

Hospitals and clinics accounted for 59.35% of 2025 revenue in the burn care market. Level I burn centers integrate intensive care, surgical suites, and rehabilitation teams to manage complex trauma. The USD 650 million Military Burn Research Program funds innovations such as deployable resuscitation units, reinforcing hospital capabilities. Emergency departments also function as gatekeepers, initiating NPWT or graft placement before step-down to outpatient settings.

Ambulatory surgery centers are expected to register a 9.72% CAGR through 2031 as portable NPWT and advanced dressings enable same-day procedures. Smart bandages like iCares permit real-time monitoring outside hospital walls, giving clinicians confidence to shorten inpatient stays. Reimbursement incentives for site-of-service shifts, together with patient preference for home recovery, support ambulatory adoption. Vendors tailoring packaging and staff training for outpatient workflows will capture incremental opportunities in the burn care market.

Geography Analysis

North America Burn Care Market

North America held 39.28% of global revenue in 2025. Federal investments, including the USD 650 million Military Burn Research allocation, promote basic and translational science. CMS updates on skin-substitute coverage effective April 2025 further incentivize technology uptake. The Los Angeles wildfires exposed 41,000 people and demonstrated the region’s vulnerability. Canadian wildfires affected 2.7 million hectares and sent smoke toward 117 million Americans, indicating cross-border healthcare contingencies.

Europe Burn Care Market

Europe combines strict regulatory oversight with rising wildfire activity around the Mediterranean. Healthcare systems focus on cost-effectiveness, prompting hospitals to adopt dressings that reduce total hospitalization days. Joint EU research programs foster collaboration between academic groups and device makers, accelerating approvals of smart hydrogel dressings.

APAC Burn Care Market

Asia-Pacific is projected to achieve an 7.78% CAGR to 2031. Policymakers prioritize universal health coverage and invest in trauma infrastructure, creating strong tailwinds in the burn care market. A region-wide consensus issued new burn-assessment guidelines and emphasized workforce training. Private-equity interest grows as healthcare providers consolidate and seek digital-health partnerships.

MEA and South America Burn Care Market

Middle East & Africa and South America remain nascent yet show steady uptake of portable NPWT and silver dressings. Governments modernize emergency services to meet climate-related disaster demands. Multilateral aid and public-private collaborations introduce telehealth solutions for remote burn triage, gradually expanding the burn care market footprint in underserved regions.

Regulatory Landscape

Burn care products span medical devices (advanced dressings, NPWT systems, and emerging non-thermal plasma equipment) and biologics/skin substitutes, so market access depends on both quality-system controls for devices and therapy-specific expectations for clinical evidence. In the United States, FDA positioning for burn-related products continues to rely on its framework for developing products for chronic cutaneous ulcers and burn wounds, while device categorization remains active in the FDA classification system (including product code OJJ for burn kits without drugs, updated in April 2026). The compliance burden is rising for novel modalities: IEC issued IEC 60601-2-91:2026 in June 2026, adding particular safety and essential performance requirements for non-thermal plasma wound treatment equipment, and ISO published ISO 10993-6:2026 in April 2026, tightening expectations for local-effects biocompatibility testing relevant to implantable or longer-wear materials used in advanced wound therapies.

In Europe, Regulation (EU) 2017/745 (MDR) remains the central framework for device approvals and post-market oversight through the 2026 consolidated text, shaping evidence packages for class III and implantable wound-care devices and certain skin-substitute delivery systems. EMA also updated its procedural documentation for parallel joint scientific advice for high-risk medical devices on May 29, 2026, reinforcing the route for developers to align clinical and regulatory strategy earlier in the product cycle. Clinical-development standardization is also being refreshed through professional and scientific channels, including a June 2026 proposed addendum from the Wound Care Collaborative Community to modernize the 2006 FDA guidance with updated reporting standards such as WRAHPS, which can raise the bar for preclinical and translational documentation for advanced burn-care technologies.

Market Opportunities and Future Outlook

Retail and outpatient channels are a clear whitespace for standardized, easy-to-use burn-care regimens that link first aid and cleansing with advanced dressings. A concrete signal came in March 2026, when Sonoma Pharmaceuticals launched an HOCl-based burn relief hydrogel through major US retailers (CVS and Walmart), indicating growing interest in scalable, consumer-accessible products that can also complement clinic pathways. At the same time, site-of-care shifts toward ambulatory and home settings support vendors that package advanced dressings, portable NPWT, and training-enabled protocols to reduce dressing-change complexity and enable telehealth follow-up.

Technology-led opportunities are concentrated in biologics and active platforms that address infection, inflammation, and tissue remodeling rather than passive coverage alone, but adoption is gated by evidence generation and reimbursement scrutiny. Multi-center studies and late-stage development activity provide near-term commercialization pathways, including MediWound's VALUE global study launch in June 2026 (216 patients across the US, Europe, and Israel) using burn-derived enzymatic technology (EscharEx) in chronic wounds, and B&K Corporation's Phase IIIa clinical trial initiation in May 2026 for a rhPDGF-BB gel in deep second-degree burns. With CMS updating skin-substitute policy in April 2025 and the American Burn Association publishing the 2025 Burn Nursing Scope and Standards to standardize specialty practice, suppliers that pair clinically differentiated products with documentation-ready workflows and workforce support tools can better address adoption barriers across both high-income and emerging markets.